Context Therapeutics (NASDAQ:CNTX), Inc. is a clinical-stage biotechnology company focused on the development of precision oncology therapies for women’s cancers. Founded in 2018 and headquartered in the Boston area, the company applies molecular and genomic insights to advance targeted treatments for hormone-driven malignancies such as breast, ovarian and endometrial cancer. Context leverages a biomarker-driven approach to identify patient populations most likely to benefit from its investigational agents, with an emphasis on oral small molecule programs.
The company’s lead product candidate, CTX001, is an oral selective estrogen receptor degrader (SERD) currently in Phase 2 clinical trials for estrogen receptor–positive breast cancer. In parallel, Context is advancing CTX110, a PARP inhibitor being evaluated in patients with BRCA-mutated ovarian cancer, and CTX140, a next-generation CDK4/6 inhibitor designed for hormone receptor–positive breast malignancies. Each of these agents is being studied as monotherapy or in combination with standard-of-care regimens across the United States and Europe, leveraging strategic trial sites and translational research collaborations.
Context Therapeutics pursues a nimble business model that combines in-licensing of promising oncology compounds with disciplined internal research and development. The company has built partnerships with leading academic centers and biotechnology firms to support preclinical validation, biomarker discovery and clinical execution. Through these alliances, Context aims to streamline the path from early-stage research to pivotal studies while maintaining a capital-efficient development strategy.
The management team is led by President and CEO John Tighe, a biotechnology executive with more than 20 years of experience in oncology drug development. The scientific leadership includes veterans in medicinal chemistry, translational oncology and regulatory affairs who have held senior roles at major pharmaceutical companies. Context Therapeutics continues to expand its pipeline, engage key opinion leaders and explore combination strategies that address unmet needs in women’s health and oncology.
